ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 315 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,601 | -24.6% | 990 | 0.0% | 0.02% | -20.0% |
| Q2 2023 | $35,303 | +40.4% | 990 | 0.0% | 0.03% | +15.4% |
| Q1 2023 | $25,146 | -37.4% | 990 | 0.0% | 0.03% | -27.8% |
| Q4 2022 | $40,154 | +21.7% | 990 | 0.0% | 0.04% | +16.1% |
| Q3 2022 | $33,000 | -5.7% | 990 | 0.0% | 0.03% | +3.3% |
| Q2 2022 | $35,000 | -23.9% | 990 | 0.0% | 0.03% | -6.2% |
| Q1 2022 | $46,000 | -30.3% | 990 | 0.0% | 0.03% | -20.0% |
| Q4 2021 | $66,000 | +32.0% | 990 | +23.8% | 0.04% | +25.0% |
| Q3 2021 | $50,000 | -24.2% | 800 | 0.0% | 0.03% | -25.6% |
| Q2 2021 | $66,000 | +24.5% | 800 | 0.0% | 0.04% | +16.2% |
| Q1 2021 | $53,000 | -13.1% | 800 | 0.0% | 0.04% | -19.6% |
| Q4 2020 | $61,000 | +177.3% | 800 | +60.0% | 0.05% | +142.1% |
| Q3 2020 | $22,000 | +46.7% | 500 | +42.9% | 0.02% | +26.7% |
| Q2 2020 | $15,000 | – | 350 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |